Aasandha states coverage for insulin has not stopped

Aasandha has denied claims that the company has stopped coverage of insulin.

They went on to say that they have not, at any point, stopped handover of insulin, a vital medication for those with diabetes.

"We urge the stoppage of information that may build displeasure or mistrust in the hearts of citizens for political purposes," Aasandha said in a post.

Diabetes is one of the bigger diseases Aasandha covers financially:

- MVR 101 million in 2021.

- MVR 152.9 million in 2022.

- MVR 164.7 million in 2023.

A cost of MVR 517 million has been spent by Aasandha over diabetes within a five-year (up to last year November) timeframe.

50 percent of Aasandha's budget had already been exhausted by May this year. The state budget had set aside MVR 1.8 billion this year, with MVR 950 million having been spent by May.